Russia begins application of personalized NeoOncovac vaccine against melanoma in Kursk patient

Centro Nacional of Pesquisa of Radiologia Médica of Ministério of Saúde of Rússia performed the first application of the NeoOncovac personalized vaccine in a controlled clinical environment. A 60-year-old man, resident in the region of Kursk, was the first patient to receive the therapeutic vaccine after being diagnosed with cutaneous melanoma, one of the most aggressive types of skin cancer. The procedure marks a significant advancement in modern oncology by utilizing messenger RNA (mRNA) technology to create a treatment tailored specifically to the genetic code of an individual’s tumor. Esta innovative approach seeks to offer a more precise and effective alternative for patients facing advanced stages of the disease.
The implementation of this technology is the result of a joint effort between Centro Nacional, Pesquisa Gamaleya, Epidemiologia and Microbiologia and Russian medical radiology experts. The development of NeoOncovac followed strict safety and efficacy protocols before receiving authorization for official clinical use on Russian territory. Health authorities highlight that this is the first global approval for a fully personalized mRNA vaccine aimed at directly combating existing malignant tumors. The treatment strategy does not focus on primary prevention, like conventional vaccines for infectious diseases, but rather on active immunotherapy to eradicate cancer cells in patients with a confirmed diagnosis.
- The 60-year-old patient received staggered doses on days 1, 8 and 15.
- The therapeutic scheme provides for the administration of boosters every 21 days.
- The complete treatment can reach a total of 10 individual applications.
- Manufacturing each personalized dose takes three to four months.
Technical functioning of messenger RNA technology in oncology treatment
The basis of NeoOncovac’s functioning lies in the ability to program the patient’s immune system to identify specific proteins that exist only in tumor cells. By analyzing tissue extracted by biopsy or surgery, scientists can map the unique genetic mutations of that cancer and translate this information into an mRNA sequence. Quando injected, the vaccine instructs defense cells to recognize these specific markers, allowing a targeted and extremely precise attack. Essa selectivity is crucial to ensure that the body’s defense system destroys threats without harming adjacent healthy tissues, reducing side effects common in traditional chemotherapies.

The preparation process requires complex logistics that necessarily begin with the collection of a viable sample of the patient’s tumor tissue. Após After extraction, the material undergoes detailed genetic sequencing in highly complex laboratories to identify the neoantigens, which are the targets of the vaccine. Durante the immunizing agent production period, which takes around 120 days, the patient is not left unassisted and generally starts conventional immunotherapy protocols with checkpoint inhibitors. Essa combination sets the biological stage so that, when NeoOncovac is finally administered, the body is in ideal conditions to respond to the genetic stimulus and combat the progression of metastases.
Eligibility criteria and clinical stages for applying the vaccine
The clinical protocol established by Ministério da Saúde da Rússia clearly defines who can benefit from this new personalized treatment modality. Atualmente, the vaccine is indicated for adult patients diagnosed with cutaneous melanoma in stages IIB, III and IV, including situations where the initial surgery has already been performed. The main focus is on individuals with inoperable cases or those with distant metastases, as long as there is no involvement of the central nervous system or active brain metastases. The absence of brain involvement is a strict technical criterion to ensure patient safety during the inflammatory response generated by the vaccine.
In addition to advanced cases, NeoOncovac is also aimed at patients who have undergone surgical removal of metastatic lesions and require adjuvant therapy to prevent recurrences. Personalized medicine is particularly useful for those who have not responded adequately to first-line treatments or who have disease recurrence without the presence of new brain metastases. The integration of Centro Gamaleya’s bioinformatics software allows treatment to be fine-tuned even for rare melanoma variants, providing renewed hope for cases that were previously considered difficult to manage therapeutically.
- Confirmed diagnosis of cutaneous melanoma between stages IIB and IV.
- Availability of fresh tumor tissue for whole genomic analysis.
- Patients who have not yet started systemic treatments for the current phase.
- Individuals with relapses after previous conventional treatments.
Prospects for expansion to other types of malignant tumors
The leadership of Centro Nacional from Pesquisa Médica to Radiologia expressed optimism about the future of this technological platform and its versatility in other scenarios. Embora cutaneous melanoma was chosen for the premiere due to its high mutation load, which facilitates the identification of targets, the methodology can be adapted. If the results observed in patient Kursk and the other initial participants are positive, the researchers plan to expand the tests to lung carcinomas, kidney and colorectal tumors. The agility of the regulatory model recently implemented in Rússia allowed the transition from the laboratory to the hospital to occur quickly, respecting biosafety standards.
Russian innovation uses biological components and proprietary software tools, which guarantees technological autonomy in the production of these high-cost medicines. The director of Centro Gamaleya highlighted that the genetic construct used in NeoOncovac is highly stable and capable of generating a robust and long-lasting T cell response. Este “Training” of the immune system aims to create a biological memory that can guard the body against the resurgence of cancer in the long term. The international scientific community is closely monitoring the survival and clinical response data that will be published in the coming months after the completion of the first therapeutic cycles.
Administration protocol and strict medical monitoring
NeoOncovac administration is not an isolated event, but rather an ongoing process that requires constant monitoring by the oncology and radiology team. The first patient at Kursk is undergoing frequent imaging and blood tests to assess the activation of expected immunological markers. The first three initial doses, applied at weekly intervals, serve to “present” the antigen to the immune system, while subsequent doses every 21 days reinforce the genetic message. Esse Escalation is critical to avoid exaggerated systemic adverse reactions and allow the body to gradually adjust to personalized treatment.
The involvement of cutting-edge institutions like Centro Nacional of Pesquisa at Radiologia ensures that the patient has access to a complete infrastructure to deal with any complications. Combining the vaccine with immune checkpoint inhibitors is a deliberate strategy, as these drugs “take the brakes off” the immune system, while the NeoOncovac vaccine provides the correct “target.” Essa synergy is the big bet by Russian doctors to increase remission rates in metastatic melanomas that previously had poor prognoses. The success of this initial case could dictate the pace of adoption of this therapy throughout the Federação Russa public health network in the coming years.
Patient safety and minimization of damage to healthy tissue
One of the most celebrated differentiators by NeoOncovac developers is the safety profile intrinsic to personalized messenger RNA technology. Diferente of radiation therapy or chemotherapy, which can affect rapidly dividing cells throughout the body, the mRNA vaccine focuses exclusively on the genetic signatures found in the individual’s tumor. Isso means that the cells of the immune system are trained to ignore normal cells in the skin, organs and blood, concentrating all their destructive potential only on the tumor mass. Essa Surgical precision at the molecular level is what defines 21st century precision oncology, transforming cancer treatment into a much more tolerable process for the elderly patient.
The 60-year-old patient’s journey in Kursk symbolizes the beginning of a new era where cancer diagnosis is no longer fought with generic tools, but with tailored solutions. The initial tissue collection and waiting time for manufacturing are offset by the high specificity of the final drug, which acts as a biological “guided missile.” Clinical monitoring will continue intensively, and the data collected will serve as a basis for the constant improvement of artificial intelligence algorithms that help in choosing the best neoantigens for the next vaccines produced. Russian science reaffirms its position at the forefront of biotechnology by delivering a treatment that combines the most modern in genetics and clinical immunology.






